Travere Therapeutics (TVTX) Total Current Liabilities (2012 - 2026)

Travere Therapeutics (TVTX) has 15 years of Total Current Liabilities data on file, last reported at $125.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 31.25% year-over-year to $125.4 million; the trailing twelve-month figure through Mar 2026 stood at $125.4 million (down 31.25% YoY), and the FY2025 full-year result was $159.9 million, down 20.35% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $125.4 million, down from $159.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $200.8 million in Q4 2024 and bottomed at $119.5 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $139.4 million (2023), against an average of $151.7 million.
• The widest annual swing landed in 2025, when Total Current Liabilities jumped 56.3%; it then plunged 31.25% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $142.2 million in 2022, then grew by 25.14% to $177.9 million in 2023, then advanced by 12.84% to $200.8 million in 2024, then declined by 20.35% to $159.9 million in 2025, then declined by 21.55% to $125.4 million in 2026.
• The last three Total Current Liabilities figures came in at $125.4 million (Q1 2026), $159.9 million (Q4 2025), and $135.1 million (Q3 2025), per Business Quant data.

Peer Comparison